BG60833B2 - Теофилин-лекарствена форма с удължено действие - Google Patents
Теофилин-лекарствена форма с удължено действие Download PDFInfo
- Publication number
- BG60833B2 BG60833B2 BG098598A BG9859894A BG60833B2 BG 60833 B2 BG60833 B2 BG 60833B2 BG 098598 A BG098598 A BG 098598A BG 9859894 A BG9859894 A BG 9859894A BG 60833 B2 BG60833 B2 BG 60833B2
- Authority
- BG
- Bulgaria
- Prior art keywords
- theophylline
- matrix pellets
- dosage form
- pellets
- matrix
- Prior art date
Links
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 title claims abstract description 186
- 229960000278 theophylline Drugs 0.000 title claims abstract description 92
- 230000000694 effects Effects 0.000 title abstract description 7
- 239000008188 pellet Substances 0.000 claims abstract description 76
- 239000011159 matrix material Substances 0.000 claims abstract description 65
- 239000000126 substance Substances 0.000 claims abstract description 23
- 239000012528 membrane Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000011248 coating agent Substances 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims abstract description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 48
- 239000002552 dosage form Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 17
- 239000000725 suspension Substances 0.000 claims description 14
- 238000005507 spraying Methods 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 5
- 229920003086 cellulose ether Polymers 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 238000007493 shaping process Methods 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000001856 Ethyl cellulose Substances 0.000 description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 8
- 235000019325 ethyl cellulose Nutrition 0.000 description 8
- 229920001249 ethyl cellulose Polymers 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000008055 phosphate buffer solution Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000012237 artificial material Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- -1 carboxyl groups organic compound Chemical class 0.000 description 3
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 3
- 230000002060 circadian Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000027771 Obstructive airways disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH611184 | 1984-12-21 | ||
| CH268385 | 1985-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG60833B2 true BG60833B2 (bg) | 1996-04-30 |
Family
ID=25691137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG098598A BG60833B2 (bg) | 1984-12-21 | 1994-02-28 | Теофилин-лекарствена форма с удължено действие |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4803080A (zh) |
| EP (1) | EP0185331B1 (zh) |
| KR (1) | KR920006910B1 (zh) |
| CN (1) | CN1008060B (zh) |
| AU (1) | AU581274B2 (zh) |
| BG (1) | BG60833B2 (zh) |
| CA (1) | CA1261268A (zh) |
| CS (1) | CS396391A3 (zh) |
| DE (1) | DE3572924D1 (zh) |
| DK (1) | DK164843C (zh) |
| ES (1) | ES8704079A1 (zh) |
| FI (1) | FI84782C (zh) |
| GR (1) | GR853051B (zh) |
| HU (1) | HU193359B (zh) |
| IE (1) | IE58246B1 (zh) |
| IL (1) | IL77322A (zh) |
| NO (1) | NO171827C (zh) |
| NZ (1) | NZ214534A (zh) |
| PT (1) | PT81714B (zh) |
| SK (1) | SK278868B6 (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753945A (en) * | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
| GB8628728D0 (en) * | 1986-12-02 | 1987-01-07 | Euro Celtique Sa | Spheroids |
| EP0327295A3 (en) * | 1988-02-01 | 1989-09-06 | F.H. FAULDING & CO. LTD. | Tetracycline dosage form |
| US5196203A (en) * | 1989-01-06 | 1993-03-23 | F. H. Faulding & Co. Limited | Theophylline dosage form |
| US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| DE3929864A1 (de) * | 1989-09-08 | 1991-03-14 | Nordmark Arzneimittel Gmbh | Verfahren zur herstellung von theophyllin-pellets |
| GB2284761A (en) * | 1993-12-03 | 1995-06-21 | Euro Celtique Sa | Prophylactic treatment of asthma |
| KR20070095456A (ko) * | 2005-01-27 | 2007-09-28 | 알렘빅 리미티드 | 레베티라세탐의 서방형 제제 |
| US20080014271A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
| CA2841748C (en) | 2011-07-15 | 2021-06-15 | Nusirt Sciences, Inc. | Compositions and methods for modulating metabolic pathways |
| CN108295058A (zh) | 2012-11-13 | 2018-07-20 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
| US20150359771A1 (en) | 2013-01-15 | 2015-12-17 | Nusirt Sciences, Inc. | Treating pulmonary conditions |
| EP2968333B1 (en) | 2013-03-15 | 2022-01-12 | NuSirt Sciences, Inc. | Leucine and nicotinic acid for the reduction of lipid levels |
| KR20160119863A (ko) | 2014-02-27 | 2016-10-14 | 뉴서트 사이언시스, 인크. | 간 지방증의 감소 또는 예방을 위한 조성물 및 방법 |
| EP3284795B1 (en) * | 2015-04-16 | 2023-08-02 | The School Corporation Kansai University | Use of a purine base-containing polymer as an anti-ice nucleation activator |
| CN106176682A (zh) * | 2016-08-30 | 2016-12-07 | 铜陵翔宇商贸有限公司 | 茶碱缓释制胶囊剂及其制备方法 |
| WO2020067887A1 (en) | 2018-09-24 | 2020-04-02 | Erasmus University Medical Center Rotterdam | Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses |
| GB202001237D0 (en) * | 2020-01-29 | 2020-03-11 | Sisteks D O O | Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1091289B (de) * | 1956-01-25 | 1960-10-20 | Hans Lowey | Verfahren zur Herstellung einer oral anzuwendenden Arzneiform mit verlaengerter Wirkungsdauer |
| DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| ATE34300T1 (de) * | 1981-07-15 | 1988-06-15 | Key Pharma | Theophyllin mit verlaengerter abgabe. |
| US4587118A (en) * | 1981-07-15 | 1986-05-06 | Key Pharmaceuticals, Inc. | Dry sustained release theophylline oral formulation |
| US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
| IE55745B1 (en) * | 1983-04-06 | 1991-01-02 | Elan Corp Plc | Sustained absorption pharmaceutical composition |
| DE3435325A1 (de) * | 1983-04-09 | 1986-04-17 | Nikken Chemicals Co., Ltd., Tokio/Tokyo | Langzeitwirkende theophyllin-tablette und verfahren zu deren herstellung |
-
1985
- 1985-12-10 IE IE310785A patent/IE58246B1/en not_active IP Right Cessation
- 1985-12-12 NZ NZ214534A patent/NZ214534A/xx unknown
- 1985-12-13 IL IL77322A patent/IL77322A/xx not_active IP Right Cessation
- 1985-12-13 DE DE8585115942T patent/DE3572924D1/de not_active Expired
- 1985-12-13 EP EP85115942A patent/EP0185331B1/de not_active Expired
- 1985-12-16 FI FI854973A patent/FI84782C/fi not_active IP Right Cessation
- 1985-12-18 CA CA000497980A patent/CA1261268A/en not_active Expired
- 1985-12-18 GR GR853051A patent/GR853051B/el not_active IP Right Cessation
- 1985-12-19 PT PT81714A patent/PT81714B/pt unknown
- 1985-12-20 ES ES550291A patent/ES8704079A1/es not_active Expired
- 1985-12-20 US US06/811,742 patent/US4803080A/en not_active Expired - Fee Related
- 1985-12-20 DK DK600485A patent/DK164843C/da not_active IP Right Cessation
- 1985-12-20 HU HU854936A patent/HU193359B/hu unknown
- 1985-12-20 NO NO855215A patent/NO171827C/no not_active IP Right Cessation
- 1985-12-20 AU AU51618/85A patent/AU581274B2/en not_active Expired
- 1985-12-21 KR KR1019850009678A patent/KR920006910B1/ko not_active IP Right Cessation
- 1985-12-21 CN CN85109688A patent/CN1008060B/zh not_active Expired
-
1991
- 1991-12-20 CS CS913963A patent/CS396391A3/cs unknown
- 1991-12-20 SK SK3963-91A patent/SK278868B6/sk unknown
-
1994
- 1994-02-28 BG BG098598A patent/BG60833B2/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3572924D1 (en) | 1989-10-19 |
| NO171827C (no) | 1993-05-12 |
| CN85109688A (zh) | 1986-06-10 |
| PT81714A (de) | 1986-01-01 |
| KR860004634A (ko) | 1986-07-11 |
| IL77322A (en) | 1990-07-12 |
| NO171827B (no) | 1993-02-01 |
| ES550291A0 (es) | 1987-04-01 |
| CN1008060B (zh) | 1990-05-23 |
| DK164843B (da) | 1992-08-31 |
| EP0185331B1 (de) | 1989-09-13 |
| EP0185331A1 (de) | 1986-06-25 |
| AU581274B2 (en) | 1989-02-16 |
| AU5161885A (en) | 1986-07-17 |
| HUT40334A (en) | 1986-12-28 |
| KR920006910B1 (ko) | 1992-08-22 |
| FI84782B (fi) | 1991-10-15 |
| NZ214534A (en) | 1988-08-30 |
| FI84782C (fi) | 1992-01-27 |
| PT81714B (pt) | 1988-04-21 |
| NO855215L (no) | 1986-06-23 |
| IE58246B1 (en) | 1993-08-11 |
| CS396391A3 (en) | 1992-06-17 |
| SK278868B6 (sk) | 1998-04-08 |
| DK600485D0 (da) | 1985-12-20 |
| IE853107L (en) | 1986-06-21 |
| CA1261268A (en) | 1989-09-26 |
| DK164843C (da) | 1993-01-11 |
| ES8704079A1 (es) | 1987-04-01 |
| FI854973A0 (fi) | 1985-12-16 |
| US4803080A (en) | 1989-02-07 |
| GR853051B (zh) | 1986-02-03 |
| DK600485A (da) | 1986-06-22 |
| FI854973A (fi) | 1986-06-22 |
| HU193359B (en) | 1987-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG60833B2 (bg) | Теофилин-лекарствена форма с удължено действие | |
| EP0164967B1 (en) | Pharmaceutical composition of sparingly soluble medicament and method for its preparation | |
| JP4976011B2 (ja) | 制御放出モルヒネ製剤 | |
| RU2201223C2 (ru) | Фармацевтическая композиция из множества субъединиц и способ ее получения | |
| CA2042289C (en) | Taste masking and sustained release coatings for pharmaceuticals | |
| CA2038245C (en) | Pharmaceutically useful micropellets | |
| US5527545A (en) | Liquid-suspension controlled-release pharmaceutical composition | |
| JP3011770B2 (ja) | 吸入適用のための製剤 | |
| FR2494112A1 (zh) | ||
| JPS5859916A (ja) | ブロモヘキシンの遅延放出剤型およびその製造方法 | |
| JPH10502390A (ja) | 医薬品用の徐放性マトリックス | |
| JP2599189B2 (ja) | 味覚遮蔽剤を含有している咀嚼可能な薬物錠剤 | |
| US4966770A (en) | Prednisone microencapsulated granules | |
| EP0083372B1 (en) | Sustained release theophyline | |
| JPH082783B2 (ja) | 新規な投与形態 | |
| US4656024A (en) | Galenical administration form of METOCLOPRAMIDE, method for its preparation and medicament comprising the new form | |
| CN115837012A (zh) | 一种氨氯地平干混悬剂及其制备方法 | |
| JPH0417932B2 (zh) | ||
| US5344657A (en) | Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them | |
| US3383283A (en) | Medicinal pellets coated with overlapping porous fatty acid leaflet layers | |
| JPH03118335A (ja) | 風味マスキングされたマイクロカプセル化非ステロイド系抗炎症水不溶性薬剤 | |
| CN105496967B (zh) | 盐酸雷尼替丁控释干混悬剂及其制备方法 | |
| AU3415993A (en) | Prolamine coatings for taste-masking orally-administrable medicaments | |
| CN114272233A (zh) | 一种奥司他韦组合物及其制备方法 | |
| US20130115282A1 (en) | Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof |